Biotechnology company Alvotech SA (NASDAQ:ALVO) and UK pharmaceutical company Advanz Pharma have entered into a European supply and commercialisation agreement for AVT10, Alvotech's biosimilar candidate to certolizumab pegol, the reference biologic marketed as Cimzia by UCB Pharma, Alvotech announced on Tuesday.

AVT10 is currently the only biosimilar to Cimzia in global development. Cimzia is a TNF-alpha inhibitor used to treat inflammatory diseases, including chronic rheumatic conditions, and has shown particular relevance for women of childbearing age.

In 2024, global sales of Cimzia reached USD2.3bn. Alvotech and Advanz Pharma aim to address market demand by expanding access to cost-effective biologic therapies across Europe.

This agreement builds on an existing strategic collaboration between the two companies, which includes partnerships on biosimilar candidates to over ten biologics.

Alvotech and Advanz Pharma expect to launch their first biosimilars in the European market in the fourth quarter of 2025.